Jithma Prasad Abeykoon MD

PubMed

• Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants.
  Aldo A Acosta-Medina, Jithma P Abeykoon, Saurabh Zanwar, Gordon J Ruan, Karen L Rech
  Leukemia. 2025-04-01
• Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia.
  Jonas Paludo, Jithma P Abeykoon, Nirosha D Perera, Shayna Sarosiek, Joshua Gustine
  American Journal of Hematology. 2025-03-10
• Methotrexate and cytarabine in adult LCH: High risk, high reward and maintenance free?
  Jithma P Abeykoon, Ronald S Go, Levi-Dan Azoulay, Julien Haroche
  British Journal of Haematology. 2025-02-01

Journal Articles

• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Daratumumab-Based Therapy in Patients with Heavily-Pretreated AL Amyloidosis  
  Saurabh Zanwar, Angela Dispenzieri, Wilson Gonsalves, David Dingli, Jithma P Abeykoon, Martha Q Lacy, Shaji Kumar, Nelson Leung, Morie A Gertz, Eli Muchtar, Francis Bu..., Nature

Abstracts/Posters

• Molecular Alterations in Adult Histiocytic Neoplasms
  Jithma P. Abeykoon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis
  Jithma P. Abeykoon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  Jithma P. Abeykoon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therap... 
  2019 ASCO Annual Meeting - 6/1/2019